Abstract:Human Papillomaviruses (HPV) are a diverse group of small non-enveloped DNA viruses. Some HPVs are classified as low-risk as they are very rarely associated with neoplasia or cancer in the general population, and cause lenient warts. Other HPVs are considered as high-risk types because they are responsible for several important human cancers, including cervical cancer, a large proportion of other anogenital cancers, and a growing number of head and neck cancers. Transmission of HPV occurs primarily by skin-to-skin contact. The risk of contracting genital HPV infection and cervical cancer is influenced by sexual activity. Currently two prophylactic HPV vaccines, Gardasil® (Merck, USA) and Cervarix® (GlaxoSmithKline, UK), are available and recommended for mass immunization of adolescents. However, these vaccines have limitations as they are expensive and require cold chain storage and trained personnel to administer them by injection. The use of nano or micro particulate vaccines could address most of these limitations as they are stable at room temperature, inexpensive to produce and distribute to resource poor regions, and can be administered orally without the need for adjuvants in the formulation. Also it is possible to increase the efficiency of these particulate vaccines by decorating the surface of the nano or micro particulates with suitable ligands for targeted delivery. Oral vaccines, which can be delivered using particulate formulations, have the added potential to stimulate mucosa-associated lymphoid tissue located in the digestive tract and the gut-associated lymphoid tissue, both of which are important for the induction of effective mucosal response against many viruses. In addition, oral vaccines provide the opportunity to reduce production and administration costs and are very patient compliant. This review elaborately discusses different strategies that can be pursued to develop a nano or micro particulate oral vaccine for HPV induced cancers and other diseases.

Laboratory Studies of IS Failure as Escalating Commitment to a Failing Course of Action: Overcoming the Obstacles

Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Revolutionizing cancer treatment: a comprehensive review of CAR-T cell therapy

CAR-T cell therapy: a game-changer in cancer treatment and beyond

Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures

Revolutionizing Cancer Treatments through Stem Cell-Derived CAR T Cells for Immunotherapy: Opening New Horizons for the Future of Oncology

CAR-T Cell Therapy: Revolutionizing Cancer Treatment

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

Progress and pitfalls of gene editing technology in CAR-T cell therapy: a state-of-the-art review

Emerging Cancer Immunotherapies: Cutting-Edge Advances and Innovations in Development

Effect of goldthioglucose on long-term cultures of mouse hypothalamus.

Methodology, Applications and Advancements of Car-T Cell Therapy in Malignancies

CAR T-Cell Therapy: Progress and Prospects

Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy

Strategies for Developing Oral Vaccines for Human Papillomavirus (HPV) Induced Cancer using Nanoparticle mediated Delivery System.

Advanced strategies in improving the immunotherapeutic effect of CAR‐T cell therapy

CAR T-Cell Therapy: The Next Frontier for Cancer Immunotherapy